Join NCF for Dec2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=cmKEuKfOcGw Download the presentation slides >>> ABOUT Immunotherapy is an exciting and rapidly advancing area in the treatment of neuroendocrine cancer. Join Dr. Aman Chauhan, Medical Oncologist at the University of Miami Sylvester Cancer Center, as he discusses the latest developments in immunotherapy for neuroendocrine cancer. This webinar will cover current standard-of-care treatments as well as cutting-edge clinical trials involving DLL3-targeted therapies, oncolytic viruses, CAR T-cell therapy, and combination approaches. Whether you’re newly diagnosed or exploring new treatment options, this session will help you better understand the evolving landscape of immunotherapy in neuroendocrine cancer. ABOUT DR. AMAN CHAUHAN Aman Chauhan, MD Medical Oncologist University of Miami Sylvester Cancer Center Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. TAKE ACTION VOICE epNEC Patient Survey November, 2025 People living with neuroendocrine carcinoma (epNEC) are invited to share their experiences through an online research survey. Patient insights will help inform future care, resources, and support for the neuroendocrine cancer community. If you are interested, click the link below (or scan the QR code) to enter your email address. You will receive a brief eligibility questionnaire and additional study details. If eligible, you will be invited to complete the full survey. Sign up here: https://s-hab.medefield.com/wix/p189895130943.aspx Survey invitations will be sent from invite@decipherinc.com within 2–3 days. Please check your spam or junk folder if needed. Your email will be used only to send the survey invitation and will be deleted after the study concludes. Thank you for considering taking part in this important study. WATCH https://www.youtube.com/watch?list=PLPAgUIq-85n_8IEEakNm9m3Gavmzrq6B5&v=_EEdMQLui4U EXPLORE High Grade Resources including videos, podcasts, articles and more For more on Clinical Trials and for the Ancora.ai Clinical Trial Finder, explore our Clinical Trials Guide T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET << Back STELLAR-311: Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Cancers IDENTIFIER ( ClinicalTrials.gov ) : NCT06943755 DRUG/TREATMENT : Zanzalintinib and Everolimus PHASE : 2/3 STATUS : Recruiting SPONSOR : Exelixis https://www.youtube.com/watch?v=sTWl5FZwG6k DESCRIPTION: A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors. The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors. For more information on eligibility criteria, trial locations, study details, etc., go to STELLAR-311 Clinical Trial (Exelixis) and/or ClinicalTrials.gov to view this trial here. CONTACT: Exelixis Clinical Trials, STELLAR-311 Clinical Trial (Exelixis) EMAIL: druginfo@exelixis.com PHONE: 1-888-EXELIXIS (888-393-5494) This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. OTHER HELPFUL RESOURCES: This Exelixis study site STELLAR-311 Clinical Trial (Exelixis) includes a toll-free medical information hotline, information on the study and eligibility criteria and study sites *Please note, Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials.

Join us at the 2023 LACNETS NET Cancer Day Symposium in Santa Monica, California: - Well-rounded agenda featuring NET experts from the medical community and patient stories. - Learn about active clinical trials and hear from patients who are participating in clinical trials. - Celebrate World NET Cancer Day with inspiring, original music by a NET patient. 2023 NET Cancer Day Symposium • Santa Monica, CA • @LACNETS 2023 NET Cancer Day Symposium • Santa Monica, CA • @LACNETS Play Video Share Whole Channel This Video Facebook Twitter Pinterest Tumblr Copy Link Link Copied Now Playing "NETS 101" • Jaydira Del Rivero, MD • 2023 NET Cancer Day Symposium @NCFCancer 25:45 Play Video Now Playing "Surgical Treatments" • Alexandra Gangi, MD • 2023 NET Cancer Day Symposium @NCFCancer 20:38 Play Video Now Playing "Medical Treatments" • Andrew Hendifar, MD • 2023 NET Cancer Day Symposium @NCFCancer 16:08 Play Video Agenda Speaker Bios OUR SPONSORS Agenda Read 2023 NCD: A Memorable Celebration ABOUT Join us at the 2023 LACNETS NET Cancer Day Symposium in Santa Monica, California: Well-rounded agenda featuring NET experts from the medical community and patient stories. Learn about hot topics including surgery, medical treatments, PRRT, and clinical trials. Celebrate NET Cancer Day with inspiring, original music by a NET patient. Connect with NET experts, patients and caregivers. No cost to attend. This event is made possible by the generosity of donors and sponsors. AGEN DA (Subject to change) Speakers SPEAKERS THE LATEST IN PRRT MARTIN AUERBACH, MD Nuclear Medicine, UCLA Dr. Allen-Auerbach is the Medical Director of UCLA Nuclear Medicine and Clinical Professor in Nuclear Medicine, Division of Pharmacology, at the David Geffen School of Medicine at UCLA. Apart from serving as attending physician in Nuclear Medicine, active research includes clinical studies investigating the role of molecular imaging with PET/CT to gain insights into malignant disease processes and as well as applications of Nuclear Medicine for the treatment of cancer. NETS 101 & OPPORTUNITIES TO ACCESS NET RESOURCES AND CLINICAL TRIALS JAYDIRA DEL RIVERO, MD Endocrinologist and Oncologist National Cancer Institute Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. SURGICAL TREATMENTS ALEXANDRA GANGI, MD Surgical Oncologist, Cedars-Sinai Medical Center Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. The Nuts & Bolts of PRRT LINDA (LINDY) GARDNER, MSN, RN, VA-BC Lead Nurse, Nuclear Medicine, UCLA Health Lindy has over two decades of Interventional Radiology experience prior to transitioning over to Nuclear Medicine in March of 2017. She obtained her RN qualification in 1993 from John Moores University of Liverpool, (LJMU) United Kingdom, she is a graduate from the University Of Dundee, Scotland where she received her Bachelors, and Master’s of Science in Nursing. In her Nuclear Medicine role Lindy is the lead nurse for the Peptide Receptor Radionuclide Therapy (PRRT) program, from the expanded access program (EAP) thru to the FDA approved commercial program. She has presented this program to a national and international audience; her skills are utilized as an expert liaison for institutions commencing the PRRT program, focusing on the patient experience, education, and therapy administration. Lindy is the nursing pillar lead for The International Center for Precision Oncology foundation (ICPO), with her focus on education, support and navigation for the NET patient journey. She is also the lead nurse for Radio-Ligand Therapy (RLT) for prostate cancer within Theranostics at UCLA, covering both clinical application and research. Lindy is a member of the Association for Radiologic and Imaging Nursing (ARIN), and the Association for Vascular Access (AVA), holding her board certification in vascular access (VACC). She sits as a member on The Healing NET Scientific Advisory Committee. CLINICAL TRIALS 101 J. RANDOLPH HECHT, MD Medical Oncologist, UCLA Health Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht attended medical school at Eastern Virginia Medical School. He took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has lead and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents. MEDICAL TREATMENTS ANDREW HENDIFAR, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. HOW PATIENT PREFERENCES IMPACT TREATMENT DECISIONS DANENG LI, MD Medical Oncologist, City of Hope Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li embraces a multidisciplinary approach to treatment of patients with neuroendocrine tumors. He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics. Nationally, he has served on several NET committees including the NANETS Research Committee, NANETS Continuing Medical Education Committee, and the Patient-Physician Communication Task Force for the Healing NET Foundation, allowing him to work closely to support NET patient advocacy programs. For all his efforts, he was honored as a recipient of the inaugural 40 Under 40 in Cancer Award during the American Society of Clinical Oncology annual meeting in 2018. PIANO CONCERT TOM BAJORAS Composer & NET Patient Tom Bajoras began playing piano and composing music as a young child growing up in Pennsylvania. Music has been his constant companion ever since, leading him to Los Angeles, where he pursued dual careers in music and music technology. In 1991 he founded a company that develops custom software for the entertainment industry. In January 2015 Tom's life took a sudden detour when he was diagnosed with metastatic pancreatic NET. This prompted an early retirement from his software company, which allowed him to work full-time in his home studio. He currently records his own music, as well as producing music for other artists and spoken-word projects such as audiobooks and podcasts. In 2018 Tom released a CD, Surprised By Beauty, a collection of music he wrote during the first two years of his journey with NET. Since then he has written a wide variety of music, videos, and poetry, all focused on discovering beauty in unexpected places. He finds joy through sharing his music and stories of hope in small, intimate concerts. When not creating in his studio or performing for audiences, Tom enjoys travel, theater, and hiking with his wife, Lisa, and their rescue dog, Skyler. THANKS TO OUR SPONSORS Up The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.

Find neuroendocrine tumor diet and nutrition resources, including guidance for NET patients, carcinoid syndrome, recipes, webinars, and expert advice. Neuroendocrine Tumor Diet & Nutrition Resources NUTRITION & RECIPE BOOKS “Food You Love” Cookbook for NETs Request a FREE copy from TerSera! Click here Nutrition & Neuroendocrine Cancer Booklet by NET Dietician Tara Whyand Download here Culinary Kit for Neuroendocrine Tumor Patients Download here Culinary Kit for NET Patients with Carcinoid Syndrome Download here Xermelo - Ask a Clinical Nurse Educator A designated Clinical Nurse Educator will be assigned to you at no cost to provide you with individualized support and answer questions about the management of carcinoid syndrome including symptom management and and how to keep a food journal. Note: it’s not just for those on xermelo. Click here for more information EDUCATIONAL WEBINARS "Nutrition & Diet Considerations" with Meghan Laszlo, MS, RD, CSO Download presentation slides >>> "Nutrition Therapy for NETs" with Meghan Laszlo, MS, RD, CSO "Nutrition & Neuroendocrine Cancer" with Tara Whyand, MSc, BSc "Luncheon with the Experts," featuring Sina Teskey, a dietician who specializes in GI cancers and neuroendocrine tumor patients. Also Watch: Carcinoid Cancer Foundation Video with NET Nutritionist Leigh Ann Burns PODCAST The LACNETS Podcast: Nutrition for NETS Meghan Laszlo, MS, RD, CSO of Cedars-Sinai Medical Center answers the top 10 NET nutrition questions, covering topics including carcinoid syndrome, prescription enzymes, diarrhea, recommended diet for NET patients, and much more! Listen Here The LACNETS Podcast: Diarrhea and NETS NET expert and gastroenterologist Dr. David Metz joins us for this month’s episode to answer the top 10 GI questions for NETs. Dr. Metz addresses diarrhea, diet, carcinoid syndrome and effective symptom management. Listen Here The LACNETS Podcast: Nutrition & Diet Considerations for NET NET dietician Sina Teskey from the Medical College of Wisconsin answers common questions about diet and nutrition raised among NET patients and caregivers. She addresses special diets, food restrictions, and whether sugar “feeds” cancer. Sina also speaks to diarrhea, and digestive enzymes and shares tips on how to maintain nutrition and weight. Listen Here Meghan Laszlo, MS, RD, CSO Meghan Laszlo MS, RD, CSO is an oncology dietitian at Cedars-Sinai in Los Angeles, California. For individuals outside of Cedars-Sinai, Meghan Laszlo sees patients through Nourish, a telehealth platform that accepts insurance (Aetna, BCBS, Cigna, United). Insurance for telehealth is available to those residing in Arizona, California, Colorado, Connecticut, Hawaii, Idaho, Indiana, Massachusetts, Michigan, New Hampshire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming! Phone: 424-235-5026 ADDITIONAL NUTRITION RESOURCES Carcinoid Cancer Foundation's Nutrition Resources NET Research Foundation’s Nutrition Resources

Join NCF for Neuroendocrine Cancer Day 2026. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page REGISTER DATE Sunday, November 8, 2026 8:30 AM - 3 PM LOCATION JW Marriott Las Vegas Resort & Spa 221 N Rampart Blvd Las Vegas, NV 89145 The 2026 NET Cancer Day Symposium will bring the neuroendocrine cancer community together in Las Vegas, Nevada, on Sunday, November 8th, for a day of education, connection, and awareness. Hosted by the Neuroendocrine Cancer Foundation, this in-person educational event is designed for patients, caregivers, families, and others seeking trusted, expert-led information about neuroendocrine cancer. ABOUT Hear presentations from neuroendocrine cancer experts and stories from those in the neuroendocrine cancer community. Learn about the latest in surgery, medical treatments, PRRT, symptom management, and clinical trials. Ask questions during the live question and answer sessions. Find out how you can spread awareness about neuroendocrine cancer. Kick-off reception with welcome breakfast. Lunch will be provided. This event is made possible by the generosity of donors and sponsors. AGENDA The full agenda and speaker list will be announced soon. Please check back closer to the event for the most accurate information. The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

Access detailed neuroendocrine cancer treatment guidelines to enhance patient care and improve outcomes. Your resource for informed decisions. NET Guidelines for Effective Neuroendocrine Cancer Treatment "Understanding NET Guidelines" with Dr. Jaydira Del Rivero Click here to download presentation slides>>> Español Guidelines for Neuroendocrine Tumor Patients by NCCN Download Here Guías ASCO (Español) Guidelines for Medical Professionals by NCCN Download Here Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline Read Here Explore More Clinical Tools & Resources Information from the American Society of Clinical Oncology (ASCO) for people with cancer, families, and caregivers Patient Information (Types of Treatment for Pancreas NET) Patient Information (Types of Treatment for GI Tract NET) NANETS Guidelines for Neuroendocrine Tumors by the North American Neuroendocrine Tumor Society Download Here To access NANETS' NET guidelines by topic, simply click on each link below. Practical Considerations when providing Palliative Care to patients with Neuroendocrine Tumors in the context of routine disease management or hospice care Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of High Grade Gastroenteropancreatic and Gynecologic Neuroendocrine Neoplasms 2021 The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma 2021 CommNETS/NANETS Guidelines for the Diagnosis and Management of Patients With Lung NETs: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines 2020 The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors 2020 The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors 2020 NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy 2019 NANETS/SNMMI Procedure Standard for Somatostatin Receptor Based Peptide Receptor Radionuclide Therapy with 177Lu-Dotatate 2017 The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society 2017 The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors 2017 (Joint with SNMMI) Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors 2013 Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors 2010 The North American Neuroendocrine Tumor Society (NANETS) Guidelines: Mission, Goals, and Process Guidelines for Neuroendocrine Tumors by the European Neuroendocrine Tumor Society (ENETS) Read Here To access the ENETS guidelines by topic, simply click on each link below. ENETS guidance paper for nonfunctioning pancreatic neuroendocrine tumours published on 5 October 2023 ENETS guidance paper for appendiceal neuroendocrine tumours published on 16 August 2023 ENETS guidance paper for functioning pancreatic NET syndromes published on 20 June 2023 ENETS guidance paper for colorectal neuroendocrine tumours published on 2 June 2023 ENETS guidance paper for gastroduodenal NET G1-G3 published on 20 May 2023 ENETS guidance paper for digestive neuroendocrine carcinoma published on 1 March 2023 ENETS guidance paper for carcinoid syndrome and carcinoid heart disease published on 25 April 2022 Gastroenteropancreatic Neuroendocrine Neoplasms: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up by the North American Neuroendocrine Tumor Society Download Here Explore the Interactive/Pocket Guideline Here

Medical Treatments/Sequencing Treatments < Back to Topics Play Video Play Video 01:24:02 Practical Tips in Managing Neuroendocrine Cancer Care • • Sep 29, 2026 ABOUT Join Taymeyah and Tiffany as they share important insights to help you spearhead your medical team and confidently navigate your healthcare. Gain practical logistics for managing the ongoing cycle of scans, lab work, and "ologist" appointments. Discover well-informed, real-world suggestions on finding and building strong partnerships with your providers and specialists. We hope this discussion empowers you to effectively and efficiently coordinate your care. Visit the event page at https://www.ncf.net/events/sep2026 Play Video Play Video 35:11 14. Panel: Navigating Treatment Decisions• Drs. Del Rivero, Chandrasekharan, Clarke and Mittra In this panel from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Jaydira Del Rivero of the National Cancer Institute moderates a discussion on Navigating Treatment Decisions for people living with neuroendocrine tumors. Panelists Dr. Chandrikha Chandrasekharan of MD Anderson Cancer Center, Dr. Callisia Clarke of the Medical College of Wisconsin, and Dr. Erik Mittra of Oregon Health & Science University discuss how treatment decisions are made across specialties, including medical oncology, surgical oncology, and nuclear medicine. The panel explores how clinicians evaluate symptoms, tumor grade, Ki-67, imaging results, somatostatin receptor status, disease burden, surgery, chemotherapy, PRRT, and other treatment options. The discussion also highlights the importance of multidisciplinary tumor boards, center-of-excellence care, patient goals, quality of life, second opinions, patient education, and support from the neuroendocrine cancer community. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net. For more information about this conference, visit https://www.ncf.net/events/2026conference This video is for educational purposes only and is not a substitute for professional medical advice. Please consult your medical team with questions about your individual care or treatment. #NeuroendocrineCancer #NeuroendocrineTumors #NETCancer #NETs #TreatmentDecisions #MultidisciplinaryCare #PRRT #Chemotherapy #CancerSurgery #TumorBoard #PatientEducation #CancerSupport #NCF #PatientConference #CancerEducation Play Video Play Video 15:26 12. Navigating Treatment Sequencing • Dr. Pamela Kunz • Yale Medicine • 2026 NCF Conference In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Pamela Kunz, medical oncologist at Yale School of Medicine and Yale Cancer Center, presents “Navigating Treatment Sequencing.” Dr. Kunz explains how treatment sequencing helps identify the right treatment at the right time for people with neuroendocrine tumors and neuroendocrine carcinomas. She discusses how treatment plans may change over time and why decisions are often guided by factors such as functional status, primary tumor site, disease stage, tumor volume, differentiation, grade, somatostatin receptor status, patient goals, and quality of life. This presentation reviews major treatment categories, including somatostatin analogs, radioligand therapies, targeted therapies, chemotherapy, liver-directed therapy, surgery, observation, and clinical trials. Dr. Kunz also explains how treatment sequencing differs for neuroendocrine tumors and neuroendocrine carcinomas, and highlights the importance of shared decision-making, multidisciplinary care, and asking whether a clinical trial may be appropriate. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net. For more information about this conference, visit https://www.ncf.net/events/2026conference This video is for educational purposes only and is not a substitute for professional medical advice. Please consult your medical team with questions about your individual care or treatment. #NeuroendocrineCancer #NeuroendocrineTumors #NETCancer #NETs #TreatmentSequencing #CancerTreatment #SomatostatinAnalogs #RadioligandTherapy #Chemotherapy #TargetedTherapy #ClinicalTrials #PamelaKunz #YaleCancerCenter #NCF #PatientConference Play Video Play Video 14:24 9. Navigating SSAs and Chemotherapy • Dr. Guillaume Pegna • Oregon Health & Science University In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Will Pegna, neuroendocrine tumor medical oncologist at Oregon Health & Science University in Portland, presents “Navigating Somatostatin Analogs and Chemotherapy for Neuroendocrine Tumors.” Dr. Pegna explains how somatostatin analogs and chemotherapy fit into the neuroendocrine tumor treatment journey. He discusses the role of octreotide and lanreotide in helping control tumor growth and hormone-related symptoms, including carcinoid syndrome, as well as when treatment may need to move beyond somatostatin analogs. This presentation also covers chemotherapy options for neuroendocrine tumors, including CAPTEM, streptozocin-based therapy, and platinum-based regimens for more aggressive disease. Dr. Pegna explains how treatment decisions are individualized based on tumor behavior, symptoms, side effects, quality of life, patient goals, and clinical trial opportunities. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net. For more information about this conference, visit https://www.ncf.net/events/2026conference This video is for educational purposes only and is not a substitute for professional medical advice. Please consult your medical team with questions about your individual care or treatment. #NeuroendocrineCancer #NeuroendocrineTumors #NETCancer #NETs #SomatostatinAnalogs #Octreotide #Lanreotide #Chemotherapy #CAPTEM #CarcinoidSyndrome #ClinicalTrials #OHSU #NCF #PatientConference #CancerEducation Play Video Play Video 01:33:06 Novel Targeted Therapies in Neuroendocrine Cancers • 2026 NCF Event • Mar 9, 2026 Some Topics Covered: Neuroendocrine, NET, NEC, High-grade Clinical trials, PRRT, RLT, Antibody Drug Conjugate (ADC), DLL3 ABOUT Learn from a discussion of targeted therapies in neuroendocrine cancer, one of the fastest-growing areas of NET treatment. Unlike traditional chemotherapy, targeted therapies focus on specific pathways or features of cancer cells. Understanding how these treatments work can help patients feel more confident and informed when discussing options with their care team. In this session, Dr. Rohit Thummalapalli, medical oncologist at Memorial Sloan Kettering Cancer Center, explores novel, innovative targeted treatments used or being studied in NETs, such as DLL3 and antibody–drug conjugates (ADCs). Dr. Thummalapalli will explain what these therapies are, how they work, and why they are becoming increasingly important in NET care. Whether you’re newly diagnosed or considering later-line treatments, this webinar will help you better understand the evolving landscape of targeted therapy and what it may mean for your care. Visit the event page at https://www.ncf.net/events/mar2026 Play Video Play Video 39:29 16. Expert Panel: Systemic Therapies & Sequencing Treatments • Hecht, Gangi, Mittra & Zhen Expert Panel: What Matters Most in Making Decisions About Systemic Therapies & Sequencing Treatments 2025 Neuroendocrine Cancer Foundation Annual Patient Conference Panelists: J. Randolph Hecht, MD Medical Oncologist UCLA Alexandra Gangi, MD Surgical Oncologist Cedars-Sinai Medical Center Erik Mittra, MD, PhD Nuclear Medicine Oregon Health & Science University David B. Zhen, MD Medical Oncologist Fred Hutch Cancer Center @NCFCancer Play Video Play Video 18:44 12. What Matters About Systemic Treatments • Jennifer Chan, MD, MPH • @NCFCancer "What Matters About Systemic Treatments" 2025 Neuroendocrine Cancer Foundation Annual Patient Conference Jennifer Chan, MD, MPH Medical Oncologist Dana-Farber Cancer Institute @NCFCancer Play Video Play Video 17:19 6. Managing Side Effects of Systemic Therapy • Dr. Jason Starr • 2025 NET Cancer Day Symposium Dr. Jason Starr speaks about "Managing Side Effects of Systemic Therapy" at the 2025 NET Cancer Day Symposium. The 2025 NET Cancer Day Symposium was a collaboration between the Neuroendocrine Cancer Foundation and the Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, in Miami, Florida, on Sunday, November 9th. #netcancer #neuroendocrinecancer #netawareness #rarecancer #cancercommunity #advocacy #ncf #lacnets #AboveAndBeyondAward #netcancerday #cancereducation #netsupport Play Video Play Video 15:49 4. Targeted Therapies & Chemotherapy • Dr. Udhayvir Grewal • 2025 NET Cancer Day Symposium Dr. Udhayvir Grewal speaks about the "Targeted Therapies & Chermotherapy" at the 2025 NET Cancer Day Symposium. The 2025 NET Cancer Day Symposium was a collaboration between the Neuroendocrine Cancer Foundation and the Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, in Miami, Florida, on Sunday, November 9th. #netcancer #neuroendocrinecancer #netawareness #rarecancer #cancercommunity #advocacy #ncf #lacnets #AboveAndBeyondAward #netcancerday #cancereducation #netsupport Play Video Play Video 19:11 07. Systemic Therapy for NETs: Treatment Options for Metastatic Tumors • Heloisa Soares, MD, PhD Play Video Play Video 01:30:51 "Understanding Treatments for NETs and Rationale for Sequencing of Therapy" • Dr. Wolin • Apr 1, 25 Learn from internationally-renowned neuroendocrine cancer expert Dr. Edward Wolin in a discussion on the latest in neuroendocrine tumor treatments and understanding how to sequence them. Dr. Wolin has pioneered many of the NET treatments including somatostatin analogues (SSAs, sandostatin and octreotide), mTOR inhibitors (i.e. everolimus), anti-angiogenic drugs (i.e. cabozantinib), and peptide receptor radiotherapy (PRRT, i.e. Lutathera). Join us for an insightful presentation and live question and answer session. Learn more at https://www.ncf.net/events/apr2025 Play Video Play Video 53:12 Episode 40: "NEN Treatments: Focus on External Radiation Therapy" ABOUT THIS EPISODE What is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing. TOP TEN QUESTIONS ABOUT EXTERNAL RADIATION THERAPY FOR NEUROENDOCRINE CANCERS: 1. What is radiation oncology? How does it work? How is it different from other types of radiation? 2. What are the types of radiation therapies used for neuroendocrine cancer? 3. Which neuroendocrine cancers are they used for, and when are they used? How do you decide who is a good candidate and if it will be effective? - Where in the body can SBRT be used? (bone, liver, pancreas, rectal?) Where can it not be used in the body, and when is SBRT NOT used? - Is there a number or size limit of the tumor(s)? 4. For Bone: How do NETs affect the bones? Are they “on” or “in” the bone, and does the tumor tend to weaken it? - If given to the bone, does SBRT weaken the bone? What are the chances of fracture with radiation to the bone? Does it matter which area of the bone/body is treated? What other factors influence fracture risk? (age, dose, number of treatments)? Should patients have a bone density scan before SBRT? - If bone lesions are causing pain, how soon after treatment might a patient expect to have pain alleviated? - How common is increased pain after treatment to the bone? What causes that? 5. Safety: - How much radiation is given with these procedures? Is there a concern about radiation safety following the procedures? (Do patients need to avoid others in the hours or days after the treatment?) - Is there a lifetime limit to the amount of radiation one can receive, especially considering surveillance CT & PET scans? - How often can these procedures be repeated? - Does it damage other tissues or organs? How common are secondary cancers? What types and how treatable are they? - Is there a risk with fertility? - What other risks are there? 6. How do these therapies compare to PRRT or radioembolization in terms of safety? If someone has had PRRT or radioembolization, can they also receive radiation therapy to the liver or bones? Is there increased risks if someone has had PRRT, radioembolization or CAPTEM or alkylating agents? 7. Is there an optimal sequence for treatments? 8. What is SBRT like for patients? What is the planning and preparation process? How do you determine how many treatments and what dose to give? 9. What does the patient experience during and after the procedure? Does it hurt? What are the side effects? How much time do I need to take off of work? 10. How effective is SBRT in terms of managing symptoms? How effective is SBRT in controlling or destroying the tumor? How do you know if the treatment “worked”? Bonus: What is the future of radiation therapy in neuroendocrine cancer treatment? For more information, visit LACNETS.org/podcast/40 Play Video Play Video 47:48 Episode 39: "NEN Treatments: Focus on Liver-Directed Therapies (Part II) In this 2-part series, Dr. Osman Ahmed from the University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this second episode, he details the embolization techniques, including bland embolization (TAE), chemoembolization (TACE), and radioembolization (TARE, SIRT, y90). He discusses decision-making, sequencing, and follow-up after these procedures. Play Video Play Video 31:32 Episode 38: "NEN Treatments: Focus on Liver-Directed Therapies (Part 1) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this first episode, he outlines the types of liver-directed therapies and elaborates on ablative techniques including the newest technique, histotripsy. Listen to a frank discussion of how histotripsy works, when it might be used, and what its current limitations are. MEET DR. OSMAN AHMED Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. TOP TEN QUESTIONS ABOUT LIVER-DIRECTED THERAPY INCLUDING HISTOTRIPSY: 1. What is liver-directed therapy? How does it work? Is this considered “surgery”? What is a surgery and what is a “procedure?” 2. What are the types of liver-directed therapies used for neuroendocrine cancer? 3. Which neuroendocrine cancers are they used for and when are they used? How do you decide who is a good candidate and if it will be effective? 4. When are liver-directed therapies NOT used? Can someone who has had a Whipple undergo liver-directed therapy? 5. What is the ablation zone? What is a heat sink effect? 6. What is histotripsy? How does it work? 7. When is histotripsy used (tumor grade, type of tumor - PNET/lung NET, size, number of tumor, location)? Can they be used for liver tumors even if there are tumors outside the liver? 8. What are the limitations to histotripsy? 9. What happens to the liver tissue after ablation? What are the results or success rates of patients being treated? Can histotripsy “cure” NET? 10. How do you decide between the various types of liver-directed therapies? For more information, transcript and resources, visit https://www.lacnets.org/podcast/38. Play Video Play Video 39:13 Episode 36 - NEN Treatments: Focus on Immunotherapy • Dr. Jennifer Eads ABOUT THIS EPISODE What is immunotherapy? How effective are they for neuroendocrine neoplasms (NENs)? Dr. Jennifer Eads from Penn Medicine answers common questions about immunotherapy. She discusses the latest in CAR T therapy, DLL3, and vaccine therapy for NENs. MEET DR. JENNIFER EADS Dr. Jennifer Eads is an associate professor of medicine at the University of Pennsylvania, Abramson Cancer Center where she is a gastrointestinal medical oncologist focusing on the treatment of and research in patients with neuroendocrine tumors and gastroesophageal cancers. She is the Physician Lead for GI Clinical Research, overseeing the Penn GI clinical research portfolio. She is the Penn institutional principal investigator for the Eastern Cooperative Oncology Group (ECOG-ACRIN) and serves as the Director of the National Clinical Trials Network (NCTN) for the Abramson Cancer Center. She has served as principal investigator for multiple phase I/II/III clinical trials, including as the national study chair for multiple cooperative group trials. She has served on the National Clinical Cancer Network (NCCN) neuroendocrine tumors guidelines committee, is a former member of the North American Neuroendocrine Tumor Society (NANETS) Board of Directors and is currently on the Board of Scientific Advisors for the Neuroendocrine Tumor Research Foundation (NETRF). In 2022, she was named as the ECOG-ACRIN Young Investigator of the Year. TOP TEN QUESTIONS ABOUT NEN TREATMENTS: 1. What is immunotherapy? How does it work? 2. How does immunotherapy differ from other treatments? 3. When is immunotherapy used? Which neuroendocrine cancers are they used for? 4. What are the various immunotherapy drugs used for neuroendocrine cancer and how do they work? What are immune checkpoint inhibitors? 5. What is CAR-T therapy? 6. What is DLL3? 7. What is vaccine therapy? 8. What side effects might someone have when taking immunotherapy? How does it make me look (will I lose my hair)? How will it make me feel (will I be able to work)? Does immunotherapy cause someone to be immunocompromised? What monitoring needs to be done while on immunotherapy? 9. How do you decide when to use immunotherapy, which to use, and for what patient? 10. What do you see as the future of immunotherapy in neuroendocrine cancer treatment? For more information, visit https://www.lacnets.org/podcast/36 Play Video Play Video 36:39 Episode 35 - NEN Treatments: Focus on Chemotherapy • Dr. Pamela Kunz ABOUT THIS EPISODE What is chemotherapy? When are they used for neuroendocrine neoplasms (NENs)? Dr. Pamela Kunz from Yale Medicine discusses the benefits, potential side effects and latest advances in chemotherapy for NENs. She explains how it differs from other treatments for NENs and how she counsels patients as they consider chemotherapy. MEET DR. PAMELA KUNZ Dr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine where she also serves as the Director of the Center for GI Cancers and Division Chief of GI Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several key leadership positions in the field including President Emeritus of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the NCI and standing member of FDA’s Oncology Drug Advisory Committee. She was recently appointed Editor-in-Chief of JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and in 2021, she was awarded ‘Woman Oncologist of the Year’ by Women Leaders in Oncology for her work in promoting gender equity. TOP TEN QUESTIONS ABOUT NEN TREATMENTS: 1. What is chemotherapy? How does it work? 2. What are the chemotherapy drugs used for neuroendocrine cancer? When are they used? Which neuroendocrine cancers are they used for? 3. How does chemotherapy differ from other treatments such as SSAs or targeted therapies (everolimus, sunitinib, cabozantinib)? 4. What side effects might someone have when taking chemotherapy? Will my hair fall out? How might it affect my day-to-day ability to work and function? Can I live a “normal life” while taking this medication? Do any of these side effects have long-lasting effects? 5. Would taking chemotherapy cause someone to be immunocompromised? 6. When in one’s neuroendocrine journey might you recommend chemotherapy? Where does it fall in sequencing? 7. How do you decide which chemotherapy medication to recommend? Can they be stopped and restarted? Can they be repeated? 8. Can you take more than one drug in the category? Can they be taken in combination with another drug? 9. Does taking chemotherapy preclude someone from getting another treatment in the future such as Lutathera PRRT or a clinical trial of alpha PRRT? 10. What do you see as the future of chemotherapy in neuroendocrine cancer treatment? For more information, visit https://www.lacnets.org/podcast/35 Play Video Play Video 54:40 Episode 34 - NET Treatments: Focus on PRRT • Dr. Riham El Khouli ABOUT THIS EPISODE What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances. MEET DR. RIHAM EL KHOULI, MD, PHD Associate Professor of Radiology, UK College of Medicine Chief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics (NM/MI&R) Director, Radiotheranostics Program University of Kentucky Dr. Riham El Khouli, MD PhD, is the director of the Radiotheranostics program and Chief of the division of NM/MI&R at the University of Kentucky and an Associate Professor of Radiology, Nuclear Medicine and Molecular Imaging at UK school of Medicine. The Radiotheranostics Program at UK is a multidisciplinary program that provides state of art standard of care clinical radiopharmaceutical therapy (RPT) techniques as well as a robust research program that constantly runs multiple RPT clinical trials aiming to explore new RPT management options for various cancers. Dr. El Khouli is fellowship trained double board certified, ABR and ABNM, academic Nuclear Radiologist with two decades of clinical and research experience. Her research initially focused on the evaluation and improvement of the acquisition and interpretation of advanced MRI techniques such as dynamic contrast enhanced (DCE) MRI, Diffusion weighted imaging (DWI), and 1H MR Spectroscopy in breast cancer. On 2013, Dr. El Khouli started a new journey in Nuclear Medicine, Molecular Imaging and Radioheranostics (NM/MI&R) and completed a nuclear medicine and dedicated PET/CT fellowships. During her new training, her passion toward molecular imaging and PET/CT grew and she participated in multiple nuclear medicine and PET/CT related research projects. Dr. El Khouli is passionate about research and education and active in the field of neuroendocrine tumor. She is one of the key team members of the dedicated biweekly intramural NET tumor boards. She also attended and presented in multiple regional NANETS and NET awareness group meetings (NCAN). Dr. El Khouli serves as a peer reviewer for multiple prestigious Journals such as Radiology and Radiographics, among others, and is an active member of the Radiologic Society of North America (RSNA), Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the American College of Radiology (ACR). She serves as an active member of the RSNA Awards Committee, RSNA Scientific Abstract Review Committee, and Radiographic NMMI review panel committee. Dr. El Khouli is an active panel member of multiple ACR Appropriateness Criteria Panels. TOP TEN QUESTIONS ABOUT NET TREATMENTS: 1. What is PRRT? How does it work? 2. What is theranostics and what does it mean? What are the terms radiotheranostics, radiopharmaceutical, radioligand therapy, PRRT? 3. How do you determine who is eligible for PRRT? 4. When is PRRT given in one’s treatment journey? 5. How does PRRT differ from other treatments? 6. What are the common side effects of Lutathera? a. Does Lutathera have long-lasting effects? b. Would receiving Lutathera affect one’s blood counts? c. How might Lutathera affect one’s liver function? When, if ever is there concern about liver failure? 7. How might PRRT affect my quality of life and my day-to-day ability to work and function? What is the risk and effects of radiation with receiving Lutathera? a. What precautions do I need to follow? b. Can I hug my child? Can I pet my dog? c. Would receiving Lutathera cause someone to be immunocompromised? 8. How to you decide who should get PRRT? a. What is peritoneal disease and how effective is PRRT with peritoneal disease? 9. How do you assess the response to PRRT? 10. What advances in PRRT are you most excited about? For more information, visit https://www.lacnets.org/podcast/34 Play Video Play Video 48:21 Episode 33: Focus on Targeted Therapies • Dr. Scott Paulson ABOUT THIS EPISODE What are Targeted Therapies and how do they work? How and when would they be used in NETs? Dr. Scott Paulson from Baylor Cancer Center in Dallas discusses common questions and concerns about targeted therapies including side effects, dosing and treatment sequencing. Bonus: Dr. Paulson shares how we can learn from Harry Potter’s invisibility cloak in understanding treatment goals with NETs. MEET DR. SCOTT PAULSON Dr. Paulson is a medical oncologist and the medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center in Dallas, Texas. He also serves as the co-director of the Gastrointestinal Research Program for the Sarah Cannon Research Institute. Dr. Paulson earned his medical doctorate at The University of Texas Southwestern Medical School. He took his residency and an internship in internal medicine at Brigham and Women's Hospital in Boston, Massachusetts. His fellowship was completed in medical oncology at the University of California, San Francisco. Dr. Paulson is active in clinical research focused on neuroendocrine tumors as well as cancers of the pancreas, liver, esophagus, stomach, and colon. Dr. Paulson is active in clinical research focused on neuroendocrine tumors as well as cancers of the pancreas, liver, esophagus, stomach, and colon. He currently is an investigator on a clinical trial studying nab-sirolimus, a mTOR inhibitor, which is a type of targeted therapy. TOP TEN QUESTIONS ABOUT TARGETED THERAPIES FOR NETs: 1. What are targeted therapies? Are they considered chemotherapy? How do they work? 2. What are the different types of targeted therapies for NETs? 3. When and how are targeted therapies used? 4. What side effects might someone have when taking a targeted therapy? a. Can targeted therapies affect blood sugars or cause diabetes? b. Can targeted therapies cause one to be immunocompromised? c. Can targeted therapies affect one’s blood counts? 5. What is the goal of treatment with targeted therapies? (Why would one take these drugs given the potential side effects? Can the side effects be managed?) 6. How do you decide which targeted therapy to recommend for a patient? 7. Can a NET patient take more than one drug in this category? Can the medications be stopped and restarted? 8. What is your approach with dosing? 9. What is your approach with monitoring? What and how often do people need blood work? 10. Does taking a targeted therapy preclude someone from getting another treatment in the future, such as Lutathera/PRRT, or a clinical trial of alpha PRRT? BONUS: What are the latest advances in targeted therapy? What is the future of targeted therapies? For more information, visit https://www.lacnets.org/podcast/33 Play Video Play Video 53:53 Episode 32: Focus on Somatostatin Analogues (SSAs) How do SSAs work? Should all NET patients be on one? What are the side effects? Dr. Edward Wolin from Mount Sinai Health System answers several common questions about the current and future role of somatostatin analogues in NET treatment. MEET DR. EDWARD M. WOLIN Professor of Medicine, Medical Oncology, Icahn School of Medicine Director, Center for Carcinoid and Neuroendocrine Tumors Tisch Cancer Institute, Mount Sinai Health System Dr. Edward M. Wolin is an internationally renowned authority on neuroendocrine tumors. Dr. Wolin is the Director of the Center for Carcinoid and Neuroendocrine Tumors at the Tisch Cancer Institute at Mount Sinai and Professor of Medicine, Medical Oncology at the Icahn School of Medicine at Mount Sinai. The multidisciplinary Center for Carcinoid and Neuroendocrine Tumors features a robust research program with clinical trials aimed at finding the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches in molecular imaging for diagnosis. Dr. Wolin has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy. Prior to joining Mount Sinai, Dr. Wolin was Director of the Neuroendocrine Tumor Program at Montefiore Einstein Cancer Center. Previously, he worked for more than two decades with Cedars-Sinai Medical Center in Los Angeles, where he founded and directed one of the largest Carcinoid and Neuroendocrine Tumor Programs in the country, and subsequently directed the Neuroendocrine Tumor Program at University of Kentucky. Dr. Wolin is also the Co-Medical Director for the Carcinoid Cancer Foundation and is on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research. He has published in many prestigious journals, including the New England Journal of Medicine and Journal of Clinical Oncology, and is a reviewer for numerous journals, including Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The Lancet Oncology. During Dr. Wolin’s two decades at Cedars-Sinai Medical Center in Los Angeles, he developed a close friendship with LACNETS founder Giovanna Joyce Imbesi. Dr. Wolin was instrumental in the co-founding and development of LACNETS. LACNETS has always been very dear to his heart and he cherishes and honors the memory of Giovanna. Dr. Wolin earned his medical degree from Yale School of Medicine. He completed both his residency in internal medicine and fellowship in medical oncology at Stanford University Hospital. He was also a clinical fellow at the National Cancer Institute of the National Institutes of Health. Dr. Wolin is board certified in internal medicine and medical oncology. TOP TEN QUESTIONS ABOUT SOMATOSTATIN ANALOGUES (SSAs) FOR NETS: (1) What are somatostatin analogues (SSAs)? How do they work? (2) When and how are SSAs used? (3) Which SSA should a patient be on? What is the difference? How do you decide? Do SSAs shrink tumors? (4) How do you know if a SSA will be helpful? Should ALL NET patients be on a SSA? (5) What about patients whose tumors don’t “light up” on a DOTATATE scan? (6) How long can someone stay on a SSA? Do SSAs stop working after a period of time? Do people develop a “resistance” to the medication? (7) What side effects may patients experience from the shot? What can patients do to prevent or manage these symptoms? How might it affect one’s day-to-day ability to work and function? Can I live a “normal life” while taking this medication? Many patients complain of diarrhea after getting the shot. What might you recommend to prevent or manage diarrhea from the injection? I’ve heard SSAs cause issues with the gallbladder. Could you explain more about the possible correlation? Do SSAs cause diabetes? Many patients note soreness after getting the shot. What might you recommend to prevent soreness from the injection? (8) If the tumor is growing does this mean the SSA did not work? Do you continue it when patients are treated with another treatment? When do you stop a SSA? (9) What is the future of SSAs? I heard there is a pill that is available in a clinical trial. Can I take a pill instead of getting the injection? (10) What words of hope do you have for the NET community? For more information, visit https://www.lacnets.org/podcast/32 Play Video Play Video 43:41 Episode 30: Bone & Brain Metastases in Neuroendocrine Cancer When and how often do NETs spread to the bones or brain? How are they found? What is the treatment? Dr. Robert Ramirez of Vanderbilt University addresses concerns surrounding bone metastases (or “mets”) as well as rare brain metastases. MEET DR. ROBERT RAMIREZ, DO, FACP Dr. Robert Ramirez is a medical oncologist specializing in the treatment of thoracic and neuroendocrine malignancies and an Associate Professor of Medicine at Vanderbilt University Medical Center in Nashville, TN. He earned his medical degree from the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine. He completed an internal medicine residency at Cooper University Hospital in Camden, New Jersey. He then completed a hematology and medical oncology fellowship at the University of Tennessee Health Sciences Center in Memphis, Tennessee and served as chief fellow. He is a Fellow of the American College of Physicians, and a member of American Society of Clinical Oncology, the International Association for the Study of Lung Cancer (IASLC), and the North American Neuroendocrine Tumor Society (NANETS). He serves on the Board of Directors for NANETS as well as the Scientific Review and Research Committee. His clinical and research interests include neuroendocrine tumors (NETs) and lung cancer. He has a specific interest in NETs of the lung ranging from diffuse idiopathic pulmonary neuroendocrine tumor cell hyperplasia (DIPNECH) and carcinoid tumors to small cell lung cancer and other high-grade neuroendocrine carcinomas. He is active in clinical trial design including investigator-initiated trials. He enjoys teaching residents and fellows and has multiple publications and given many lectures for the scientific community on the topics of NETs and lung cancers. TOP TEN QUESTIONS Bone mets: 1. When and how often do NETs spread to the bones? 2. Where in the bones are tumors? What does it mean when NETs spread to the bones? How does this compare to other cancers? 3. How are bone spots found and monitored? Should they be biopsied? 4. What is the treatment for bone mets? Should I have radiation? Would radiation limit my ability to get PRRT? 5. Should I be on bone strengthening medication? Am I at higher risk for fractures (or breaking my bones) if I have NETs in the bones? 6. Do bone mets respond to PRRT? 7. Does having bone mets put me at a higher risk of MDS? Brain mets: 8. When and how often do NETs spread to the brain? Do all types of NETs have the potential to spread to the brain? 9. How are brain mets found and monitored? When should I suspect this? 10. How are brain mets treated? What does having brain mets mean for my life? *Bonus: What final words of hope do you have for the neuroendocrine cancer community? For more information, visit https://www.lacnets.org/podcast/30. Play Video Play Video 46:13 Episode 27: What to Know About Neuroendocrine Tumor Liver Metastases ABOUT THIS EPISODE What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr. Xavier Keutgen from the University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. MEET DR. XAVIER KEUTGEN Xavier M. Keutgen MD is a board-certified, double-fellowship trained surgeon who specializes in the treatment of gastro, entero, pancreatic neuroendocrine tumors and neoplasms of the thyroid, parathyroid and adrenal glands. A native from Belgium, Dr. Keutgen graduated magna cum laude from the University of Heidelberg Medical School in Germany and completed a general surgery residency and surgical oncology research fellowship at New York Presbyterian Hospital-Weill Cornell Medical Center. He then completed a hepato-pancreato-biliary fellowship at the University Hospital of Zurich in Switzerland as well as an endocrine oncology and surgery fellowship at the National Cancer Institute, National Institutes of Health (NIH) in Bethesda, Maryland. Dr. Keutgen currently serves as the director of the Neuroendocrine Tumor Program, director of the Endocrine Research Program and co-director of the Von Hippel-Lindau Clinical Care Program at the University of Chicago Medicine. Throughout his career Dr. Keutgen has developed a particular interest in clinical, translational and basic science research. His laboratory specializes in investigating the role of radiation therapy and DNA damage repair in pancreatic, lung and small bowel neuroendocrine tumors, discovering new actionable molecular targets for neuroendocrine tumors, and elucidating new mechanisms of drug delivery for endocrine malignancies. TOP TEN QUESTIONS 1. What is liver NETs? How often do NETs spread? Is it expected that NETs will eventually spread? 2. If the primary tumor was already removed, do you now call this liver NET or do you still refer to it by the primary site of origin – and why? How is this different from liver cancer? 3. What causes NETs to spread? Is there anything that is done to cause NET tumors to spread? Is there anything that can be done to keep them from spreading? 4. How do you determine if surgery is an option? What is involved in evaluating metastases? What scans or labs are needed? 5. How do you decide what the “tumor burden” is? 6. How do you weigh the grade or ki67? How do you weigh tumor size? Is there a cut-off for tumor size or the number of tumors that is too much to operate? 7. How does one decide between surgery versus other options? How often can surgery or other treatments be done? How safe is liver surgery? 8. How do you approach surgery for someone with liver tumors who also has tumors in the tail versus the head of the pancreas? 9. When someone has had a Whipple surgery and later is found to have tumors in the liver, what are the options? 10. What advances in the field are you most excited about? For more information, visit https://www.lacnets.org/podcast/27. Play Video Play Video 44:15 Episode 26 - What to Know About Lung NETs ABOUT THIS EPISODE What are lung NETs? What is DIPNECH? How is lung NET similar or different from lung cancer? Dr. Vineeth Sukrithan from Ohio State University Comprehensive Cancer Center gives a comprehensive overview of lung NET and DIPNECH, including the work-up and treatment options. He also discusses open clinical trials and exciting advances in lung NET research on the horizon. MEET DR. VINEETH K. SUKRITHAN Dr. Vineeth Sukrithan is a medical oncologist who specializes in the study and treatment of neuroendocrine cancer, thyroid cancer and adrenocortical cancer. He utilizes traditional chemotherapy, molecularly targeted oral medications, novel immunotherapy and peptide-receptor radiotherapies in the treatment of these unique cancers. As a comprehensive cancer center, the OSUCCC – James has unrivaled experience and expertise in the treatment of neuroendocrine, thyroid and adrenal tumors. Their world-renowned faculty are leaders in the study and treatments of these rare cancers, and as such, they are able to provide their patients with options beyond standard therapies that may not be available anywhere else. The strong focus on translational research at The James means that the treatment breakthroughs of tomorrow are being discovered in their laboratories today. Dr. Sukrithan is part of a tight-knit team of surgical oncologists, radiation oncologists and interventional radiologists who work together to provide cutting-edge care for our patients with neuroendocrine tumors. In addition to his clinical work, Dr. Sukrithan is a member of the Translational Therapeutics Program at the OSUCCC – James and the co-director of the Adrenal Tumor Clinic. He was recently selected to lead an externally funded effort through the International Thyroid Oncology Group to operationalize a multi-institutional registry database for patients with medullary thyroid cancer. Dr. Sukrithan also serves as an assistant professor in the Division of Medical Oncology at The Ohio State University and has completed postdoctoral fellowships in clinical research at Johns Hopkins University. His research has been published in numerous peer-reviewed journals, including Cancer Research, American Journal of Clinical Oncology and Clinical Lung Cancer. As every individual’s cancer is molecularly unique in countless ways, Dr. Sukrithan believes in tailoring therapies to the individual with the precision made available through cutting-edge scientific research. He feels it is a privilege to make a difference in the lives of patients as we work together to achieve a cancer-free world. TOP 10 QUESTIONS 1. What are lung NETs? Where are they located? 2. How are lung NETs found? What are the symptoms of a lung NET? 3. How is lung NETs different (or similar) to what is commonly referred to as “lung cancer”? 4. How is it different or similar to DIPNECH? Do all lung NET patients have DIPNECH and do all DIPNECH patients have lung NET? 5. How is lung NET similar or different from other types of NETs? What makes it unique? 6. What types of labs, scans, or testing is done to determine if someone has a lung NET and DIPNECH? What is the best type of scan for lung NETs? 7. How do you decide if the lung NET can be surgically removed? What type of surgeon would make that determination and when in their patient journey might they see a surgeon? 8. How are lung NETs treated medically (or nonsurgically)? How are the treatments different from other NETs? How are treatments sequenced? 9. How are lung NETs monitored? What types of blood work, tests and scans should be done and how often should they be done? 10. What advances in the field or clinical trials should we be aware of? What new advances or treatments in the pipeline for lung NETs are you most excited about? Play Video Play Video 45:52 Episode 25 - What to Know About Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC) ABOUT THIS EPISODE What are Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (NEC)? What makes NEC unique? Can a NET transform to NEC? Dr. Nitya Raj from Memorial Sloan Kettering Cancer Center in New York City explains NEC tumor biology and how it guides treatment strategy. She also discusses current clinical trials and research. MEET DR. NITYA RAJ Nitya Raj, MD is a gastrointestinal medical oncologist with a clinical practice devoted to caring for people with gastrointestinal and endocrine cancers, including neuroendocrine tumors, adrenal cancer, colorectal cancer, pancreatic cancer, and other gastrointestinal cancers. Dr. Raj’s research focuses on advancing treatments for neuroendocrine cancers (a rare group of tumors that often begin in the body’s digestive organs as well as adrenocortical cancers. Dr. Raj is also studying ways to improve our understanding of how neuroendocrine tumors change at the genetic level over time and as a result of different treatments, in order to better personalize our care for people with these cancers. Dr. Raj’s work has been recognized and supported by the American Society of Clinical Oncology with a Young Investigator Award and Career Development Award, as well as by the Neuroendocrine Tumor Research Foundation with a Pilot Award. Nationally, Dr. Raj serves on the Neuroendocrine Tumor Task Force of the National Cancer Institute. Dr. Raj is on the faculty of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. TOP 10 QUESTIONS 1. What is a poorly differentiated grade 3 neuroendocrine carcinoma (NEC)? Are all NEC poorly differentiated and are all poorly differentiated NEC? Where are they located? 2. How are NEC found? How does one know it is a NEC? 3. How is NEC unique compared to other types of neuroendocrine cancers? In particular, how is it different from grade 3 NET? 4. What types of labs, scans, or testing for NEC? 5. Can a NEC be surgically removed? How would you decide if, when, and how? 6. How are NEC treated medically (or nonsurgically)? 7. What treatment might you use as second-line? What is the role of liver-directed therapy? What is the role of immunotherapy? 8. What are clinical trials we should be aware of or exciting new treatments in the pipeline for NEC? 9. How are NEC monitored? What types of bloodwork or tests should be done and how often should they be done? 10. What words of hope would you like to leave the neuroendocrine cancer community with? For more information, visit https://www.lacnets.org/podcast/25. Play Video Play Video 40:58 Episode 24 - What to Know About Grade 3 Well-Differentiated NETs ABOUT THIS EPISODE What are grade 3 NETs and how is it different from grade 3 NEC and other types of NETs? Dr. Mohamad (Bassam) Sonbol from Mayo Clinic in Phoenix, Arizona, enlightens us on this fairly new entity, including treatment options, treatment sequencing and clinical trials. MEET DR. MOHAMAD BASSAM SONBOL Mohamad Bassam Sonbol, M.D., is an Oncologist, with special interest in neuroendocrine tumors and gastrointestinal malignancies. In addition to his clinical activities, Dr. Sonbol is active in research that focuses on investigating novel treatments including targeted therapies, immunotherapy, and other agents that could potentially help patients with neuroendocrine and gastrointestinal cancers. Dr. Sonbol focuses on the holistic treatment for cancer patients taking into consideration their medical and social aspects that have been affected by their cancer diagnosis. TOP 10 QUESTIONS 1) What are grade 3 NETs? Where are they located? How is grade 3 NETs different from other types of NETs? In particular, how is it different from grade 3 NEC? Can NET change into NEC? 2) How are grade 3 NETs found? How does one know it is grade 3? 3) What types of labs, scans, or testing is done to determine if someone has a grade 3 NET? 4) Can a grade 3 NET be surgically removed? How would you decide if, when, and how? 5) How are grade 3 NETs treated medically (or nonsurgically)? How are treatments sequenced? 6) How are the treatments different from other NETs? 7) How are grade 3 NETs monitored? What types of bloodwork or tests should be done and how often should they be done? What is the best type of scan for grade 3 NETs? 8) Can the tumors change in grade, Ki-67, and differentiation? What is the likelihood of NET changing to NEC and is there anything that can predict this or prevent this from happening? 9) What are clinical trials we should be aware of or exciting new treatments in the pipeline for grade 3 NETs? 10) What words of hope would you like to leave the NET community with? For more information, visit https://www.lacnets.org/podcast/24. Play Video Play Video 31:25 Episode 23 - What to Know About Hindgut & Appendiceal NETS ABOUT THIS EPISODE What are Hindgut NETs (distal colon and rectum) and how are they treated? How is rectal NET different from rectal cancer? What makes appendiceal NETs difficult to diagnose? Dr. Hagen Kennecke from Providence Cancer Institute in Portland, Oregon shares insights on the diagnosis and management of Hindgut NETs and appendix NET. MEET DR. HAGEN KENNECKE Dr. Hagen Kennecke is a Medical Oncologist and Medical Director of GI Oncology at Providence Cancer Institute and Associate Member of the Chiles Research Institute in Portland, Oregon. He has worked passionately to improve the treatment, education and outcomes of those affected by neuroendocrine tumors. Dr. Kennecke is an active clinician researcher, the recipient of numerous research awards and has authored numerous guidelines on the treatment of neuroendocrine tumors. He is a member of the US NCI GI Steering Committee and is a prior member of the NCI-NET Task Force, and has worked extensively within the neuroendocrine community including NANETS, Carcinoid Cancer Foundation, LACNETS and Healing NETS. TOP 10 QUESTIONS 1) What are hindgut NETs? Where are they located? What are the different types of hindgut NETs? 2) How are hindgut NETs found? What are the symptoms of a hindgut NET? 3) What types of labs, scans, or testing is done to determine if someone has a hindgut NET? Could you discuss why people with appendix NET often have a challenging time getting a diagnosis. 4) How is rectal NET different from rectal cancer? What are some ways that hindgut NETs differ from other types of NETs? What makes rectal NET unique? 5) How do you decide if the hindgut NET(s) can be surgically removed? What type of surgeon would make that determination? There are people diagnosed with appendix NET who have been told by their doctor to have a hemicolectomy. What is your opinion about this? 6) How are hindgut NETs treated medically or nonsurgically? 7) How are treatments sequenced? 8) How are the treatments different from other NETs? 9) How are hindgut NETs monitored? What types of bloodwork or tests should be done and how often should they be done? What is the best type of scan for hindgut NETs? 10) What are clinical trials we should be aware of or exciting new treatments in the pipeline for hindgut NETs? And what words of hope would you like to share with the NET community? For more information, visit https://www.lacnets.org/podcast/23. Play Video Play Video 44:47 Episode 22 - What to Know About Pancreatic NETs ABOUT THIS EPISODE What is the difference between Pancreatic Neuroendocrine Tumor (PNET) and Pancreatic Cancer? Where exactly is the pancreas located and why is the tumor location important? NET Oncologist Dr. Jennifer Chan from Dana-Farber Cancer Institute takes us through how some treatments, imaging and blood work are unique to PNETs. She also expounds on several ongoing and active trials. MEET THE SPEAKER JENNIFER CHAN, MD, MPH Assistant Professor of Medicine, Harvard Medical School Institute Physician, Division of Medical Oncology, Dana-Farber Cancer Institute Jennifer Chan, MD, MPH is an Associate Professor of Medicine at Harvard Medical School and Institute Physician in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA. She focuses her clinical practice on the care of patients with neuroendocrine tumors and gastrointestinal cancers. Dr. Chan is the Director of the Program in Neuroendocrine and Carcinoid Tumors and Clinical Director for the Gastrointestinal Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center. She has been principal investigator of multiple clinical trials investigating novel therapies for neuroendocrine tumors and has been involved in studies examining factors associated with clinical outcomes in patients with neuroendocrine tumors. Dr. Chan is a past chair of the Guidelines Committee of the North American Neuroendocrine Tumor Society (NANETS) and serves on the National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumors Guidelines Panel. She is a member of the Neuroendocrine Tumor Taskforce of the National Cancer Institute and the Board of Directors of NANETS. TOP 10 QUESTIONS 1. What are pancreatic NETs? Where are they located? 2. How are pancreatic NETs found? What are the symptoms of a pancreatic NET? 3. How is pancreatic NETs different from “pancreatic cancer?” How is it different from a pancreatic cyst? 4. What types of labs, scans, or testing is done to determine if someone has a pancreatic NET? 5. What are some ways that pancreatic NETs differ from other types of NETs? What makes it unique? 6. How do you decide if the pancreatic NET can be surgically removed? What type of surgeon would make that determination? 7. How are pancreatic NETs treated medically (or nonsurgically)? How are treatments sequenced? 8. How are the treatments different from other NETs? 9. How are pancreatic NETs monitored? What types of bloodwork or tests should be done and how often should they be done? What is the best type of scan for pancreatic NETs? 10. What are clinical trials we should be aware of or exciting new treatments in the pipeline for pancreatic NETs? For more resources and a transcript of this episode, visit https://www.lacnets.org/podcast22. Play Video Play Video 45:34 Episode 21 - What to Know About Small Bowel NETs ABOUT THIS EPISODE How are small bowel NETs diagnosed, treated, and monitored? How is it different from other types of NETs? What are some exciting new treatments for small bowel NETs? NET oncologist Dr. David Zhen of Fred Hutchinson Cancer Center in Seattle answers 10 common questions about small bowel NETs. MEET THE SPEAKER DAVID B. ZHEN, MD Assistant Professor, Division of Medical Oncology, University of Washington Assistant Professor, Clinical Research Division, Fred Hutchinson Cancer Center Dr. David Zhen is a medical oncologist who specializes in treating patients with gastrointestinal cancers. His research centers around the development of clinical trials evaluating new therapies and combination approaches for the treatment of patients with gastrointestinal cancers, particularly for neuroendocrine and gastroesophageal cancers. He is also conducting research to understand the interactions of the immune system in gastrointestinal cancers and how this can be manipulated to improve upon the response to immunotherapy drugs called checkpoint inhibitors, which block a braking system that cancers use to tamp down the immune response. TOP 10 QUESTIONS 1. What are small bowel NETs? Where are they located? 2. How are small bowel NETs found? What are the symptoms of a small bowel NET? 3. What types of labs, scans, or testing is done to determine if someone has a small bowel NET? Why are small bowel NETs not found in routine endoscopy or colonoscopy? 4. What are some ways that small bowel NETs differ from other types of NETs? What makes small bowel NETs unique from other types of NETs? 5. How do you decide if the small bowel NET(s) can be surgically removed? What type of surgeon would make that determination? 6. How are small bowel NETs treated medically? 7. How are treatments sequenced? 8. How are the treatments different from other NETs? 9. What are some exciting new treatments in the pipeline for small bowel NETs? What are clinical trials we should be aware of for small bowel NETs? 10. How are small bowel NETs monitored? What types of bloodwork or tests should be done and how often should they be done? What is the best type of scan for small bowel NETs? Bonus: What words of hope would you like to share with the NET community? For more resources and a transcript of this episode, visit https://www.lacnets.org/podcast21. Play Video Play Video 01:01:43 Episode 20 - Gastric NET, Gastrinomas & Zollinger-Ellison Syndrome (ZES) ABOUT THIS EPISODE Gastroenterologist and Neuroendocrinologist Dr. David C. Metz discusses important concepts in Gastric NET, Gastrinomas and Zollinger-Ellison Syndrome, including detection, treatments, associated risks and monitoring. He also lends valuable insight on ulcers, MEN and proton pump inhibitors. MEET THE SPEAKER David C. Metz, MD Professor of Medicine, Perelman School of Medicine Co-Director Emeritus, University of Pennsylvania Neuroendocrine Tumor Program After earning his MD from the University of the Witwatersrand's Medical School, Dr. Metz was a resident at both the Albert Einstein Medical Center and the Johannesburg General Hospital. He went on to complete fellowships at Georgetown University Hospital as well as the National Institutes of Health. Arriving at Penn Medicine in 1993, David Metz, MD, held a variety of leadership roles within the Department of Gastroenterology, including Co-Directorship of the Neuroendocrine Tumor Center and Penn NET Treatment Program. Dr. Metz was previously a staff fellow at the National Institutes of Health, where he performed basic research in pancreatic acinar cell secretion and clinical research in Zollinger-Ellison syndrome. While at Penn Medicine, he served as Chair of the North American Neuroendocrine Tumor Society (NANETS), as a member of the Liaison Committee for Recertification of the American Board of Internal Medicine (American Gastroenterological Association representative), and on the Food and Drug Administration Gastrointestinal Drugs Advisory Committee, among other positions. Dr. Metz's clinical interests at Penn included Zollinger-Ellison syndrome and other acid-peptic conditions, Helicobacter pylori infection, non-steroidal anti-inflammatory drug gastropathy and the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. An investigator for a series of prominent clinical trials in all of these areas, Dr. Metz has published more than 200 articles on topics of clinical interest and research. He retired in July 2021 after 28 years at Penn Medicine. In 2021 Dr. Metz received the NANETS Lifetime Achievement Award that honors an individual who, over the course of their career, has provided outstanding contributions to neuroendocrine disease management through research, clinical practice or educational initiatives, as well as exceptional leadership in NANETS and dedication to its mission. TOP 10 QUESTIONS 1. What is Gastric NET? How is it found? What are the symptoms? How does it differ from “stomach cancer” or other types of NETs? 2. How is Gastric NET treated and how is it monitored? 3. What is a Gastrinoma? How and where is it found? Are Gastrinomas and Gastric NET the same thing? 4. How is a Gastrinoma treated? 5. How is a Gastrinoma monitored? - How often do you recommend Endoscopies or Gastrin level lab testing? - Does a high Gastrin level mean someone has a Gastrinoma or are there other causes? Can you have a high Gastrin level without having a gastrinoma? 6. What is Zollinger-Ellison Syndrome? How is it found? What are the common symptoms from ZES/functioning Gastrinomas? 7. How is Zollinger-Ellison Syndrome treated? How is Zollinger-Ellison Syndrome monitored? Does ZES put you at risk for other conditions/complications? 8. What is a common Proton Pump Inhibitor dose for someone with ZES? Is there a danger in taking PPIs for a long time or in high doses? 9. I’ve been told I have an ulcer? Am I at risk for cancer? 10. What are advances for gastric nets, gastrinomas or Z-E syndrome that we should be aware of or excited about? *Bonus question: What last words of hope would you like to leave the NET community with? For more resources and the transcript of this episode, visit https://www.lacnets.org/podcast20. Play Video Play Video 16:44 "How Patient Preferences Impact Treatment Decisions" • Daneng Li, MD • 2023 NET Cancer Day @NCFCancer "How Patient Preferences Impact Treatment Decisions" • Daneng Li, MD • 2023 NET Cancer Day Symposium @NCFCancer • Santa Monica, CA Speaker: Daneng Li, MD Medical Oncologist City of Hope For more information, visit LACNETS.org. Play Video Play Video 16:08 "Medical Treatments" • Andrew Hendifar, MD • 2023 NET Cancer Day Symposium @NCFCancer "Medical Treatments" • Andrew Hendifar, MD • 2023 NET Cancer Day Symposium • Santa Monica, CA Speaker: Andrew Hendifar, MD Medical Oncologist, Cedars-Sinai For more information, visit LACNETS.org Load More < Back to Topics Next Topic >

<< Go back to the Podcast page EPISODE 29: NUTRITION & DIET CONSIDERATIONS FOR NET Download a Transcript of this Episode >> ABOUT THIS EPISODE NET dietician Sina Teskey from the Medical College of Wisconsin answers common questions about diet and nutrition raised among NET patients and caregivers. She addresses special diets, food restrictions, and whether sugar “feeds” cancer. Sina also speaks to diarrhea, and digestive enzymes and shares tips on how to maintain nutrition and weight. MEET SINA TESKEY, RD, CD Sina Teskey, RD, CD received her B.S. from the University of Wisconsin-Madison in 2006 and completed her dietetic internship at the University of Minnesota Medical College-Fairview in 2007. She has spent most of her career working with cancer and eating disorder patients. Sina practiced in the Twin Cities area for 10 years where she also spent time guest starring on a local TV show called Twin Cities Live to share nutrition advice. She moved to Milwaukee and has worked at Froedtert Hospital and the Medical College of Wisconsin since 2018. Sina sees all patients with cancer but specializes in GI cancers and neuroendocrine tumor patients. When she’s not working, Sina is a mom to three kids and a Labrador retriever. She loves to cook and bring people together with food. Her youngest son was diagnosed with Non-Hodgkin’s Lymphoma in 2019. His cancer journey gave insight into what having cancer means to a family and has impacted her practice profoundly. Her son Milo is now 7 years old and in remission. TOP TEN QUESTIONS Is there a diet NET patients should follow? Are there foods NET patients should avoid? Some people say there are certain “trigger foods” to avoid. What CAN I eat? What diet is helpful after bowel surgery? What about pancreas surgery? Are there vitamins or supplements recommended for NET patients? What can NET patients do about diarrhea? What diet or medications might help? What can NET patients do if they struggle with a poor appetite? What can NET patients do if they are struggling to keep on or gain weight? What can NET patients do to stay hydrated? What are pancreatic enzymes and how are they taken? Who are they recommended for? What proteins can people take if they are vegetarian or vegan given soy may be a trigger for carcinoid syndrome? What do you think of alternative diets such as the keto diet or other “special diets?” Does sugar feed cancer? What about intermittent fasting? RESOURCES READ LACNETS Nutrition Resources MAKE Energy Bites DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Lantheus is a leading radiopharmaceutical-focused company with proven expertise in developing, manufacturing and commercializing cutting-edge radiodiagnostics. Learn more about Lantheus' commitment to neuroendocrine tumors>> Have questions or want to learn more? Please reach out to Anita Roach, Patient Advocacy Director at Lantheus Anita.Roach@Lantheus.com This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by NCF. Talk to your medical team about your individual care and treatment.

See videos from the previous annual conferences of the Neuroendocrine Cancer Foundation Annual Conferences < Back to Topics 2023 Virtual LACNETS NET Patient Conference Play Video Play Video 13:08 Welcome & Introduction • 2023 LACNETS Neuroendocrine Tumor Patient Conference • June 17, 2023 The LACNETS team welcomes viewers to the 2023 LACNETS Neuroendocrine Tumor Patient Conference on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 21:51 NETS 101: Overview of NET Terms & Concepts • Dr. Aman Chauhan • 2023 LACNETS Patient Conference Watch "NETS 101: Overview of NET Terms & Concepts" with Dr. Aman Chauhan. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit, LACNETS.org. Play Video Play Video 27:33 A Conversation with Three NET Surgeons • Dr. Clarke, Dr. Gangi & Dr. Anaya • 2023 LACNETS Conference Watch 'A Conversation with Three NET Surgeons' featuring Dr. Callisia Clarke, Dr. Alexandra Gangi and Dr. Daniel Anaya Saenz. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 05:02 Kimberly Shares About Her NET Journey • 2023 LACNETS Patient Education Conference Kimberly shares her inspiring NET journey as part of the 2023 LACNETS Patient Education Conference. Play Video Play Video 04:49 Navigating Treatments • Moderators: Dr. Hendifar, Dr. Li & Mary Donlevy • 2023 LACNETS Conference Moderators of the 2023 LACNETS Patient Education Conference discuss "navigating treatments." For more information, visit LACNETS.org. Play Video Play Video 17:02 The Latest in Liver-Directed Therapy • Dr. Osmanuddin Ahmed • 2023 LACNETS Patient Conference Watch "The Latest in Liver-Directed Therapy" with Dr. Ahmed. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 19:08 The Latest in NET Imaging • Dr. Nadine Mallak • 2023 LACNETS Patient Education Conference Watch "The Latest in NET Imaging" with Dr. Nadine Mallak. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 17:55 The Latest in PRRT • Dr. Carina Mari Aparici • 2023 LACNETS Patient Education Conference Watch "The Latest in PRRT" with Dr. Carina Mari Aparici. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 08:50 Symptom Management & Clinical Trials • Moderators: Dr. Hendifar, Dr. Li & Donlevy • 2023 Conference Co-Moderators discuss "Symptom Management and Clinical Trials" during the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 06:59 Don & Beth Share Their NET Journey • 2023 LACNETS Patient Conference Don & Beth share their inspiring NET journey. For more information, visit LACNETS.org. Play Video Play Video 21:49 The Latest in Systemic Treatments & Considerations for Treatment Sequencing • Dr. Kunz • LACNETS Watch "The Latest in Systemic Treatments & Considerations for Treatment Sequencing" with Dr. Pamela Kunz. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 18:39 The Latest in NET Clinical Trials • Dr. Simron Singh • 2023 LACNETS Patient Education Conference Watch "The Latest in NET Clinical Trials" with Dr. Simron Singh. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 17:07 Clinical Trials: Why, What & How • Josh Mailman • 2023 LACNETS Patient Education Conference Watch "Clinical Trials: Why, What & How" with Josh Mailman. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 36:37 Live Q&A with NET Experts Moderated by Lisa Yen • 2023 LACNETS Patient Education Conference Watch NET Experts in this live Q&A moderated by Director of Programs and Outreach Lisa Yen. This Q&A is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 34:54 Live Q&A with NET Experts Moderated by Josh Mailman • 2023 LACNETS Patient Education Conference Watch NET Experts in this live Q&A moderated by President of NorCal CarciNET & Patient Advocate Josh Mailman. This Q&A is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 05:00 Closing • Co-Moderators & the LACNETS Team • 2023 LACNETS Conference Co-Moderators and the LACNETS Team close the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. 2022 Virtual LACNETS NET Patient Conference Play Video Play Video 10:49 01. Conference Welcome from LACNETS - 2022 LACNETS NET Patient Conference 2022 LACNETS NET Patient Conference Presented by LACNETS LACNETS Staff: Lindsey Jeu De Vine, Director of Communications Lisa Yen, NP, NBC-HWC, Program Director For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 15:24 02. Co-Moderators: Newly-Diagnosed + Conference Theme - 2022 LACNETS NET Patient Conference Conference co-moderators discuss what they would say to someone who has just been diagnosed with neuroendocrine cancer (NET), as well as the conference theme, "Empowering You to Make NET Decisions." 2022 LACNETS NET Patient Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai Lisa Yen, NP, HWC-NBC, Program & Outreach Director, LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 05:29 3. What is NET? Many NET patients find it challenging to explain their diagnosis to loved ones. To help patients and loved ones understand and explain neuroendocrine tumors (NETs), we created this short educational video with the help of NET experts and patient advocates. We hope this video serves as a helpful tool to share with your loved ones. For more information on neuroendocrine cancer, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Music by Tom Bajoras. Video produced by tvplive.com. Play Video Play Video 06:38 04. Patient Story: Treatment Decisions & Navigating Insurance - 2022 LACNETS NET Patient Conference Diagnosed in 2021 with NETs in the small bowel, NET Patient Julie shares her path to treatment in hopes of providing guidance to newly-diagnosed patients. 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 15:22 05. NET Surgery: Making Decisions & Preparing for Surgery (Dr. Clarke) - 2022 LACNETS Conference Dr. Callisia Clarke addresses surgery for neuroendocrine cancer including decision-making & preparing for surgery. Presenter: Callisia Clarke, MD Surgical Oncologist Medical College of WI 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 18:28 06. NET Testing: The What, When, How and Why (Dr. Namrata Vijayvergia) - 2022 LACNETS Conference Dr. Neena Vijayvergia addresses the what, when, how and why of NET testing. Presenter: Namrata Vijayvergia, MD Medical Oncologist, Fox Chase Cancer Center 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 04:29 07. Co-Moderators: Navigating Treatment Decisions Conference co-moderators discuss what they'd share with a NET patient who considering the many treatment options for NETs. 2022 LACNETS NET Patient Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai Lisa Yen, NP, HWC-NBC, Program & Outreach Director, LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 22:57 08. NET Treatments: Medical Therapies & Clinical Trials (Dr. Diane Reidy) - 2022 LACNETS Conference Dr. Diane Reidy-Lagunes joins us for her presentation on NET treatments, including medical therapies & clinical trials. *This presentation is also available in Spanish: lacnets.org/spanish-resources Speaker: Diane Reidy-Lagunes, MD Medical Oncologist, Memorial Sloan Kettering 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 15:21 09. The Latest in Liver Directed Therapy + Histotripsy (Dr. Osman Ahmed) - 2022 LACNETS Conference International radiologist Dr. Osman "Os" Ahmed addresses the latest in liver-directed therapy and histotripsy for neuroendocrine cancer. Speaker: Osman Ahmed, MD International Radiologist, University of Chicago 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 16:32 10. The Latest in NET Imaging & PRRT (Dr. Thomas Hope) Radiologist Dr. Thomas Hope addresses the latest in NET imaging and PRRT. Speaker: Thomas Hope, MD Radiologist, UCSF 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 04:44 11. Co-Moderators: Finding a “new normal” - 2022 LACNETS NET Conference Conference co-moderators discuss what they'd say to a NET patient who wonders how to find a “new normal” in this rollercoaster ride of living with NETs. 2022 LACNETS NET Patient Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai Lisa Yen, NP, HWC-NBC, Program & Outreach Director, LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 07:12 12. Patient Story: From Diagnosis to Patient Advocacy - 2022 LACNETS NET Patient Conference Diagnosed with neuroendocrine cancer (NET) in 2021, NET patient Michel shares how the lack of information and awareness of his uncommon diagnosis inspired him to start a patient support group in Mexico called NETs Mexico. This patient story is also available in Spanish, found here: www.LACNETS.org/spanish-resources 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 21:13 13. Managing NET Symptoms & Treatment Side Effects (Dr. Sandy Kotiah) - 2022 LACNETS Conference Dr. Sandy Kotiah addresses the management of #NET symptoms and treatment side effects. Speaker: Sandy Kotiah, MD Medical Oncologist, Mercy Medical 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 16:36 14. Best Outcomes for NETs (Dr. Julie Hallet) - 2022 LACNETS Conference Surgical oncologist Dr. Julie Hallet addresses how to achieve the best outcomes for NETs and what we know about how care is delivered. Speaker: Julie Hallet, MD, MSc, FRCSC Surgical Oncologist, Sunnybrook 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 15:11 15. Being an Engaged Patient (Josh Mailman) - 2022 LACNETS Conference NET patient advocate Josh Mailman discusses the importance of being an engaged patient. Speaker: Josh Mailman, MBA President, NorCal CarciNET Community 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 03:03 16. Co-Moderators: Q&A - The importance of being an engaged patient Conference co-moderators discuss the importance of being an engaged patient. 2022 LACNETS NET Patient Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai Lisa Yen, NP, HWC-NBC, Program & Outreach Director, LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 02:32 17. Learn Your NET Intro To help improve patient-physician communication, we are excited to share that we have developed another helpful communication tool for NET patients and caregivers called NET Intro. Your NET Intro is a downloadable wallet-sized card to help you learn to introduce yourself to someone who doesn’t yet know your NET history. Download your NET Intro card here: lacnets.org/netintro *A special thank you to LACNETS Program Director Lisa Yen and our weekly support group for helping us create this important tool for NETs. Play Video Play Video 01:02:59 18. Live Q&A with the NET Experts (All Speakers) - 2022 LACNETS Conference 8 NET experts from around the country join us for a live Q&A on neuroendocrine cancer. 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 05:28 19. Conference Closing Remarks from LACNETS - 2022 LACNETS Conference 2022 LACNETS NET Patient Conference Presented by LACNETS LACNETS Staff: Lindsey Jeu De Vine, Director of Communications Lisa Yen, NP, NBC-HWC, Program Director For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. 2021 Virtual LACNETS NET Patient Conference Play Video Play Video 09:41 1. Conference Welcome - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS LACNETS Staff: Lindsey Jeu De Vine, Director of Communications Lisa Yen, NP, NBC-HWC, Program Director For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 06:30 02. Co-Moderators discuss NET expert consultation and surgery - 2021 LACNETS Virtual Conference Conference co-moderators discuss NET expert consultation and surgery for NETs 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 04:40 03. Patient Story (Federico) - 2021 LACNETS Virtual Conference NET Patient Federico and his wife share their journey with NET. 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS This video is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 30:23 04. What to Expect with a NET Expert Consultation (Dr. Soares) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Heloisa Soares, MD, PhD Medical Oncologist Huntsman Cancer Institute This presentation is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 15:08 05. To Cut or Not to Cut? Surgery for NETs (Dr. Clarke) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Callisia Clarke, MD Surgical Oncologist Medical College of WI For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 03:40 06. Co-moderators discuss treatment for NETs - LACNETS 2021 Virtual Conference Conference co-moderators discuss treatment for NETs. 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 20:56 07. Surveillance, Maintenance, More Treatments (Dr. Halfdanarson) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Thorvadur (Thor) Halfdanarson, MD Medical Oncologist; Mayo Clinic For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 19:16 08. Radiation Safety with PRRT (Dr. Hope) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Tom Hope, MD Radiologist UCSF For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 17:16 09. Liver-directed Therapy (Dr. Nutting) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Charles Nutting, DO Interventional Radiologist Endovascular Consultants of Colorado For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 04:29 10. Co-moderators discuss symptom management Co-moderators discuss symptom management. 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 06:00 11. Patient Story about Symptom Management (Val) - 2021 LACNETS Virtual Conference NET Patient Val shares her experience with symptom management and NETs. 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 17:19 12. Symptom Management (Dr. Del Rivero) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Jaydira Del Rivero, MD Endocrinologist, Oncologist NIH This presentation is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 16:29 13. Complementary Medicine (Dr. Duma) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Narjust Duma, MD Assistant Professor & Thoracic Oncologist UW Madison This presentation is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 06:27 14. Co-moderators discuss NET Research, Advocacy & Support - 2021 LACNETS Virtual Conference Co-moderators discuss NET Research, Advocacy & Support 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 18:28 15. NET Research: What's on the Horizon? (Dr. Kunz) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Pam Kunz, MD Medical Oncologist Yale Cancer Center For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 05:40 16. Caregiver Story (Federico and Gilda) - 2021 LACNETS Virtual Conference NET caregiver Gilda shares her story about the importance of NET patient advocacy and support. 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS This video is also available in Spanish, found here: www.LACNETS.org/spanish-resources. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:03:41 18. Q&A with the NET Experts (All Faculty) - 2021 LACNETS Virtual Conference Description: 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS All presenters of the 2021 LACNETS Virtual Conference. For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 04:58 19. Conference Closing Remarks (Co-Moderators & LACNETS Staff) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Co-moderators: Beth DeBlase, NET Patient Mary Donlevy, NET Patient, LACNETS Board Member Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai Daneng Li, MD, Medical Oncologist, Cedars-Sinai LACNETS Staff: Lindsey Jeu De Vine, Director of Communications Lisa Yen, NP, NBC-HWC, Program Director For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. 2020 Virtual LACNETS NET Patient Conference Play Video Play Video 42:50 Finding a NET Expert + Surgery for NETs - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: LACNETS Conference Welcome (0:00 - 5:44) Lindsey Jeu De Vine, Director of Communications, LACNETS Lisa Yen, NBC-HWC, Program Director, LACNETS "Finding a NET Expert" (5:44 - 22:25) Cindy Lovelace , Executive Director Healing NET Foundation "Surgery for NETs" (22:25 - end of video) Alexandra Gangi, MD , Surgical Oncology Cedars-Sinai Medical Center For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:17:15 "Systemic Therapy: GI, Lung, PNETS & Unknown Primary" 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: "Patient Story" (0:00 - 7:03) Eric, NET Patient "Systemic Therapy: GI NETs" (7:03 - 28:13) Dan Li, MD , Medical Oncology City of Hope "Systemic Therapy: Lung NETs" (28:13 - 52:08) Robert Ramirez, DO, FACP, Neuroendocrine & Thoracic Oncology Ochsner Medical Center "Systemic Therapy: PNETs and NETs of Unknown Primary" (52:08 - end of video) Andrew Hendifar, MD, Medical Oncology Cedars-Sinai Medical Center For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:20:02 Imaging & Role of IR (Liver-Directed Therapy) + PRRT - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: "Patient Story" (0:00 - 6:06) Mary, NET Patient "Imaging & Role of IR (Liver-Directed Therapy)" (6:06 - 43:31) Michael C. Soulen, MD , Radiology Penn Medicine "Patient & Caregiver Story" (43:31 - 50:52) Shaunie, NET Patient; Heather, NET Caregiver "PRRT" (50:52 - end of video) Erik S. Mittra, MD, PhD, Diagnostic Radiology, Nuclear Medicine Oregon Health & Science University For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 49:02 Symptom Management: Diarrhea, Hyperglycemia & Diabetes - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: "Patient Story" (0:00 - 6:30) Brent, NET Patient "Symptom Management: Diarrhea" (6:30 - 29:05) David C. Metz, MD, Gastroenterology Penn Medicine "Symptom Management: NET-related Hyperglycemia and Diabetes" (29:05 - end of video) Run Yu, MD, PhD , Endocrinology UCLA Health For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:00:23 Live Q&A with 10 NET Experts - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Q&A Panel Speakers: • Alexandra Gangi, MD , Surgical Oncology, Cedars-Sinai Medical Center • Andrew Hendifar, MD, Medical Oncology, Cedars-Sinai Medical Center • Dan Li, MD , Medical Oncology, City of Hope • David C. Metz, MD , Gastroenterology, Penn Medicine • Erik S. Mittra, MD, PhD, Diagnostic Radiology, Nuclear Medicine, Oregon Health & Science University • Robert Ramirez, DO, FACP, Neuroendocrine & Thoracic Oncology, Ochsner Medical Center • Michael C. Soulen, MD , Radiology, Penn Medicine • Run Yu, MD, PhD , Endocrinology, UCLA Health Q&A Moderators: • Josh Mailman, MBA, President, NorCal CarciNET • Lisa Yen, NP, NBC-HWC Program Director, LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. 2019 LACNETS NET Patient Conference at Cedars-Sinai Play Video Play Video 18:10 Opening: Giovanna Imbesi & Shlomo Melmed, MB, ChB - 2019 LA NET Conf Opening: Giovanna Imbesi & Shlomo Melmed, MB, ChB Shlomo Melmed, MB, ChB, FRCP, MACP Executive Vice President of Academic Affairs, Dean of the Medical Faculty and Professor of Medicine, Cedars-Sinai Medical Center Giovanna Joyce Imbesi, MBA Executive Director, LACNETS Saturday, June 8th, 2019 www.LACNETS.org Play Video Play Video 10:18 Role of Oncologist + Year in Review: Andrew Hendifar, MD (Cedars Sinai) - 2019 LA NET Conf Role of Oncologist + Year in Review Andrew Hendifar, MD Gastrointestinal Oncology, Cedars-Sinai Medical Center Play Video Play Video 11:43 Giovanna Imbesi Cedars-Sinai Patient Leadership Award - 2019 LA NET Conf Giovanna Imbesi Cedars-Sinai Patient Leadership Award Giovanna Joyce Imbesi, MBA Executive Director, LACNETS 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 19:28 NET Vitals Workshop: Daneng (Dan) Li, MD - 2019 LA NET Conf NET Vitals Workshop: Daneng (Dan) Li, MD - 2019 LA NET Conf Download NET VITALS: www.LACNETS.org/netvitals Andrew E. Hendifar, MD, MPH Gastrointestinal Oncology, Cedars-Sinai Medical Center Daneng (Dan) Li, MD Medical Oncologist, City of Hope 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 09:31 Pathology: Alberto Marchevsky, MD - 2019 LA NET Conf Pathology: Alberto Marchevsky, MD Alberto Marchevsky, MD Professor, Pathology; Director, Pulmonary and Mediastinal Pathology, Cedars-Sinai Medical Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 34:00 Surgery - Liver + Pancreas: Kambiz Kosari, MD, FACS - 2019 LA NET Conf Surgery - Liver + Pancreas: Kambiz Kosari, MD, FACS Kambiz Kosari, MD, FACS Surgeon, Cedars-Sinai Medical Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 17:47 Surgery - GI: Farin Amersi, MD - 2019 LA NET Conf Surgery - GI: Farin Amersi, MD Farin Amersi, MD Surgical Oncology, Cedars-Sinai Medical Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 19:30 Interventional Radiology: Gabriel Lipshutz, MD - 2019 LA NET Conf Interventional Radiology: Gabriel Lipshutz, MD H. Gabriel Lipshutz, MD Interventional Radiology, Cedars-Sinai Medical Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 58:21 Tumor Board + Q&A: All Faculty - 2019 LA NET Conf Tumor Board + Q&A: All Faculty 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 11:09 NET Patient & Daughter Comedic Stand-up Piece: Andie & Terry Bolt - 2019 LA NET Conf NET Patient & Daughter Comedic Stand-up Piece: Andie & Terry Bolt Andie Bolt Comedian, TV Writer/Producer, and Podcaster Terry Bolt NET Patient 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 14:49 Functional Tumors - Carcinoid Syndrome: Daniel M. Halperin, MD - 2019 LA NET Conf Functional Tumors - Carcinoid Syndrome: Daniel M. Halperin, MD Daniel M Halperin, MD Medical Oncologist and Clinical Investigator, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 31:14 Nuclear Medicine Imaging & PRRT: Louise Thomson, MD - 2019 LA NET Conf Nuclear Medicine Imaging & PRRT: Louise Thomson, MD Louise E. Thomson, MD Nuclear Medicine, Cedars-Sinai Medical Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 11:31 Genomics: Jun Gong, MD - 2019 LA NET Conf Genomics: Jun Gong, MD Jun Gong, MD Hematology/Oncology, Cedars-Sinai Medical Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 14:58 Q&A - All Faculty - 2019 LA NET Conf Q&A - All Faculty 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 21:53 Insurance for NETs: Laurie Todd, “The Insurance Warrior” - 2019 LA NET Conf Insurance for NETs: Laurie Todd, “The Insurance Warrior” 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 45:34 Patient Panel + Above & Beyond Award- 2019 LA NET Conf Patient Panel 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org 2018 Conference at UCLA Health Playlist >>> 2017 Conference at City of Hope Playlist >>> 2016 Conference at Cedars-Sinai Playlist >>> 2015 Conference at Cedars-Sinai Playlist >>> < Back to Topics Next Topic >

RESOURCES & RESEARCH FOR PROVIDERS HYPOGLYCEMIA Are your cancer patients experiencing hypoglycemia? This is a valuable resource for physicians as we continue to build educational content in non-islet cell tumor hypoglycemia (NICTH). Key elements of the site focus on: Pathophysiology Presentation and diagnosis Limitations in current management The impact of living with NICTH Resources and FAQs Go to CancerHypoglycemia.com RESOURCES 2025 NANETS Guidelines Compendium The NANETS NET Guidelines Library offers expert clinical guidelines for healthcare professionals caring for people with neuroendocrine tumors and neuroendocrine neoplasms. Topics include diagnosis, treatment, imaging, surgery, PRRT, surveillance, palliative care, high-grade disease, lung NETs, pancreatic NETs, small bowel NETs, and pheochromocytoma/paraganglioma. This provider resource can help clinicians stay informed and support care planning for people with neuroendocrine cancer. NANETS NET Guidelines Library READ Comprehensive Overview of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Gastroenteropancreatic Neuroendocrine Tumors Vijayvergia et al., Gastroenterology (2025) https://doi.org/10.1053/j.gastro.2025.07.004 This high-quality review article provides an up-to-date, clinically relevant overview of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It summarizes current understanding of epidemiology, advances in diagnostic imaging—including the expanding role of SSTR-PET—and evidence-based management strategies across surgery, somatostatin analogs, PRRT, and emerging targeted therapies (e.g., mTOR and anti-VEGF inhibitors). An excellent reference for clinicians seeking a concise, authoritative update on the fundamentals and evolving landscape of NET care. DOWNLOAD ARTICLE Paradigm Shift in Neuroendocrine Neoplasm Classification Neuroendocrine neoplasm classification: The missing piece of the puzzle Grewal et al., Cell Reports Medicine (2025) https://doi.org/10.1016/j.medj.2025.100897 Current NET classifications mostly rely on where the tumor started (site of origin), how fast it’s growing (Ki-67), and how differentiated the cells are. This article by Grewal et al. highlights how adding molecular information—unique genetic or biological “fingerprints” of a tumor—can provide important clues about prognosis and help guide more personalized treatment options and clinical trial opportunities. The authors also show that combining advanced imaging with blood-based molecular tests can offer a clearer, more dynamic picture of how the disease is behaving. Why this matters: These advances may help patients and care teams make more informed decisions, detect changes earlier, and move toward more individualized, precision-based NET care. DOWNLOAD ARTICLE Integrating Patient Priorities Into NET Treatment Sequencing Radioligand Therapy and Sequencing in Gastroenteropancreatic Neuroendocrine Tumors: A Patient Perspective Review Lewis et al., JCO Oncology Practice (2025) https://ascopubs.org/doi/10.1200/OP-25-00474 Co-authored in partnership with patient advocates, including our Director of Programs & Outreach, Lisa Yen, this review underscores the critical role of the patient perspective in treatment planning for gastroenteropancreatic NETs. It highlights how treatment sequencing—particularly the use and timing of radioligand therapy (RLT)—can meaningfully influence both clinical outcomes and patient quality of life. The article emphasizes the importance of clear communication, transparency around rationale, and shared decision-making so that treatment plans reflect not only evidence-based best practices but also patient goals, preferences, and lived experience. TAKE-HOME MESSAGE FOR HCPs: Patients and caregivers bring essential insight into how treatments impact their daily lives, priorities, and tolerance for side effects. Inviting and integrating their perspectives—early and often—supports more individualized care, strengthens trust, and ensures that treatment sequencing aligns with what matters most to the patient, not just the disease biology. DOWNLOAD ARTICLE

Explore health and wellness resources for neuroendocrine cancer patients and caregivers, including meditation, yoga, mindfulness, and wellness coaching. Health & Wellness Resources for Neuroendocrine Cancer MEDITATION Download Insight Timer App Download Headspace App Download Mindful Meditations by UCLA MARC VIDEOS: YOGA & MEDITATION FOR NET PATIENTS & CAREGIVERS Guided Meditation with Ruth Guided Meditation with Ruth Guided Meditation with Ruth Guided Meditation with Ruth Guided meditation for self-healing Gentle yoga for body awareness Guided meditation for cultivating intentions Yoga as gentle mindful movement Looking for more yoga videos? Check out Yoga for NETs by NorCal CarciNET . FREE HEALTHING COACHING FROM LACNETS Health coaching is an opportunity for individuals to invest time and energy in self-care by going through a personal journey of change with a health coach as a guide. LACNETS offers a series of one-on-one telephonic coaching sessions (8-10 total) to NET patients and caregivers within the United States who are motivated to invest in their own self-care. Learn more here